AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 12 min read$CGTX

Cognition Therapeutics Participating in Upcoming Investor Conferences

Cognition Therapeutics (Nasdaq: CGTX) said CEO Lisa Ricciardi will present at two investor conferences in June, sharing updates on the company’s planned registrational program for dementia with Lewy body (DLB) psychosis. The Jefferies Global Healthcare Conference is June 4, 2026 (1:25 p.m. ET), with an on-demand H.C. Wainwright summit starting June 15. Webcasts will be available on the company’s site.

Original reporting
manilatimes.net
Published Jun 1, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cognition Therapeutics Participating in Upcoming Investor Conferences — source image
Source · manilatimes.net
Decision brief

The 30-second read

$CGTXNeutralLow
01

Why it matters

The news mainly flags upcoming management communication about a registrational program for DLB psychosis; without new data, it is more about monitoring than immediate repricing.

02

Market read

Near-term trading relevance is tied to what management discloses at the June conferences; the press release itself contains no new clinical or regulatory datapoints.

03

What to watch

Traders should focus on whether the company provides concrete milestones (e.g., EAP/registrational pathway details, expected submission timing) during the live/on-demand events, since that would be the first truly decision-relevant incremental information.

Relevance 6/10Novelty 4/10Timing: Ahead of the June 4 Jefferies healthcare conference and June 15 on-demand Neuro Perspectives summit.

Background

CGTX is a clinical-stage neurodegeneration company developing zervimesine (CT1812), with prior Phase 2 signals in DLB and Alzheimer’s-related indications.

Company-level read

Ticker impact

$CGTXNeutralMedium confidence
Context

Cognition Therapeutics (CGTX) said its CEO will present June updates on a registrational program for DLB psychosis tied to zervimesine (CT1812).

Expected impact

Likely limited near-term impact; any move would depend on what the CEO discloses during the June 4/15 presentations.

Evidence & confidence

The article is an investor-conference announcement with stated intent to discuss plans, not results, FDA feedback, or trial readouts.

Market effects

Sector

Adds incremental attention to DLB psychosis development programs and the broader neurodegeneration biotech conference-catalyst cycle.

Regional

None specific beyond US small/mid-cap biotech investor attention.

Global

Limited; the update is company-specific and US-focused (Nasdaq-listed issuer).

Counterpoint

What could challenge this read

If the presentations reiterate previously known registrational timelines without new FDA guidance or trial progress, the market may fade the catalyst quickly.

Key entities

  • company
    Cognition Therapeutics, Inc.

    Nasdaq-listed clinical-stage biopharma; CEO to present June updates on a DLB psychosis registrational program.

  • person
    Lisa Ricciardi

    President and CEO who intends to present at two financial conferences in June.

  • product_candidate
    zervimesine (CT1812)

    Investigational therapy; company plans late-stage development for DLB psychosis and will discuss registrational plans.

Read at source← All news

Related articles

AUG 6
$CGTXMed

COGNITION THERAPEUTICS INC (CGTX): Results of Operations and Financial Condition

COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622462d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing pr

SEC EDGAR 8-K5 min
JUN 24
$CGTXMed

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

Cognition Therapeutics said the FDA, in written meeting feedback, agreed that psychosis in dementia with Lewy bodies (DLB) could support an approvable outcome and aligned on key aspects of a pivotal NDA trial for zervimesine (CT1812). The Phase 3 program is expected to start mid-2027; it will randomize patients to 100 mg once-daily zervimesine vs placebo for nine months, using NPI as a primary endpoint.

manilatimes.net4 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min
AUG 8
$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min
AUG 8
$APLDMedAI 8/10

APLD Stock Rallies After Hours On Massive New $7.5 Billion Hyperscaler Lease: Retail Think Firm Should Be Worth More Than Rival IREN

Applied Digital (APLD) shares rose more than 7% after hours after the company said it surpassed 1 GW of contracted capacity for its AI data centers. It signed a 15-year take-or-pay lease for Polaris Forge 3 with a U.S. investment-grade hyperscaler, valued at about $7.5B base-term contracted revenue and up to $18.2B with renewals. Total contracted lease revenue across four campuses is $31B.

stocktwits.com4 min